<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.2.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
  <div style="text-align: center; color: rgb(0, 0, 0);">As filed with the Securities and Exchange Commission on April 1, 2022</div>
  <div style="text-align: right; color: rgb(0, 0, 0);">Registration No. 333-_________</div>
  <div>
    <div>
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <hr noshade="noshade" align="center" style="height: 2px; width: 20%; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;">
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">UNDER</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">PDS Biotechnology Corporation</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Exact name of registrant as specified in its charter)</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z5c567e652c6b479aa159887830fdcbc1">

        <tr>
          <td style="width: 49.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Delaware</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">26-4231384</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(State or other jurisdiction of incorporation or organization)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 49.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">25B Vreeland Road, Suite 300</div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Florham Park, NJ</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">07932</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.01%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
          </td>
          <td style="width: 2%; vertical-align: top;">&#160;</td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">&#160;(Full title of the plan)</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Frank Bedu-Addo</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">President and Chief Executive Officer</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">PDS Biotechnology Corporation</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">25B Vreeland Road, Suite 300</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Florham Park, NJ 07932</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(800) 208-3343</div>
    <div style="text-align: center; color: rgb(0, 0, 0);">(Name, address and telephone number, including area code, of agent for service)</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><font style="font-style: italic;">Copies t</font>o:</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Fahd M.T. Riaz, Esq.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Emilio Ragosa, Esq.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">DLA Piper LLP (US)</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">One Liberty Place</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">1650 Market Street, Suite 5000</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Philadelphia, PA&#160; 19103-7300</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(215) 656-3316</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; width: 40%; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;">
    <div style="color: rgb(0, 0, 0);">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z99585bfddd214707ba07bb84a7a8a6a1">

        <tr>
          <td style="width: 15%; vertical-align: middle;">&#160;</td>
          <td style="width: 35%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Large Accelerated filer &#9744;</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Accelerated filer &#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">
            <div style="color: rgb(0, 0, 0);">Non-accelerated filer &#9746;</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Smaller reporting company &#9746;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top;">&#160;</td>
          <td style="width: 35%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Emerging growth company &#9744;</div>
          </td>
        </tr>

    </table>
    <div style="color: rgb(0, 0, 0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. &#9744;</div>
    <div>&#160;</div>
    <div>
      <hr align="center" style="border-width: 1px medium 4px; border-style: solid none; border-color: black -moz-use-text-color; -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; height: 10px; color: rgb(255, 255, 255); background-color: rgb(255, 255, 255); text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Part II</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Information Required In The Registration Statement</div>
    </div>
    <div>
      <div><br>
      </div>
    </div>
    <div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">This Registration Statement relates to the registration of an additional 2,616,163 shares (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Shares</font><font style="color: rgb(0, 0, 0);">&#8221;) of PDS Biotechnology Corporation&#8217;s (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Registrant</font><font style="color: rgb(0, 0, 0);">&#8221;)
          Common Stock, par value $0.00033 per share. The Shares are securities of the same class and relate to the same employee benefit plan, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was amended and
          restated effective as of December 8, 2020 (in the form attached hereto as Exhibit 99.1) (the &#8220;</font><font style="font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">2014 Plan</font><font style="color: rgb(0, 0, 0);">&#8221;), as those
          registered pursuant to the Registrant&#8217;s registration statements on Form S-8, previously filed with the Securities and Exchange Commission on </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001396/s001068x1_s8.htm">October



          21, 2015 (Registration No. 333-207545)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761916001984/s001233x1_s8.htm">March 9, 2016 (Registration No. 333-210041)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036117010512/forms8.htm">March 3, 2017 (Registration No. 333-216430)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036118011463/s002104x1_s8.htm">March 2, 2018 (Registration No. 333-223389)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119003707/s002686x1_s8.htm">February 22, 2019 (Registration No. 333-229817)</a><font style="color: rgb(0, 0, 0);">, and </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119010389/forms8.htm">June 4, 2019 (Registration No. 333-231943)</a><font style="color: rgb(0, 0, 0);">.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">In accordance with General Instruction E of Form S-8, the contents of the Registrant&#8217;s registration statements filed with the Securities and Exchange Commission
          on </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001396/s001068x1_s8.htm">October 21, 2015 (Registration No. 333-207545)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761916001984/s001233x1_s8.htm">March 9, 2016 (Registration No. 333-210041)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036117010512/forms8.htm">March 3, 2017 (Registration No. 333-216430)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036118011463/s002104x1_s8.htm">March 2, 2018 (Registration No. 333-223389)</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119003707/s002686x1_s8.htm">February 22, 2019 (Registration No. 333-229817)</a><font style="color: rgb(0, 0, 0);">, and </font><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119010389/forms8.htm">June 4, 2019 (Registration No. 333-231943)</a><font style="color: rgb(0, 0, 0);"> are incorporated herein by reference (solely to the extent the contents of such
          registration statements relate to the 2014 Plan) and the information required by Part II is omitted, except as supplemented by the information set forth below.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="ze8f5c5b19c9b41bea25e0f067e4a7cdd">

        <tr>
          <td style="width: 36pt; vertical-align: top; color: rgb(0, 0, 0); font-weight: bold;">Item 8.</td>
          <td style="width: auto; vertical-align: top;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">Exhibits.</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zb010ba35cf4944719e950ad260dc6d0e">

        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit </div>
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">No.</div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001328/s000911x12_ex3-1.htm">4.1</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on October 6, 2015).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119005071/ex3_1.htm">4.2</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission
              on March 18, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036119005071/ex3_2.htm">4.3</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Commission
              on March 18, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036122009505/brhc10035198_ex3-1.htm">4.4</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on March 15, 2022).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000156761915001209/s000911x5_ex4-1.htm">4.5</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333- 206416) filed with the
              Commission on September 21, 2015).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10035847_ex5-1.htm">5.1*</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Opinion of DLA Piper LLP (US).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10035847_ex23-1.htm">23.1*</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Consent of KPMG LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="brhc10035847_ex5-1.htm">23.2*</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Consent of DLA Piper LLP (US) (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center; color: rgb(0, 0, 238);"><a href="brhc10035847_ex24.htm">24</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Power of Attorney (contained on the signature page hereto).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle;">
            <div style="text-align: center; color: rgb(0, 0, 0);"><a href="https://www.sec.gov/Archives/edgar/data/1472091/000114036120027857/brhc10017772_ex10-3.htm">99.1</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Commission on December 9, 2020).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="brhc10035847_ex107.htm">107*</a></div>
          </td>
          <td style="width: 92%; vertical-align: middle; background-color: rgb(204, 238, 255);">
            <div style="color: rgb(0, 0, 0);">Filing Fee Table</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" class="DSPFListTable" id="z2c1f738e6c924be583fc5cdbce7fd5ce">

        <tr>
          <td style="width: 9pt; vertical-align: top;">*</td>
          <td style="width: auto; vertical-align: top;">
            <div>Filed herewith</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"></div>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">SIGNATURE</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0);">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
      Form S-8 and has duly caused this Registration Statement with respect to the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
      of Florham Park, State of New Jersey, on April 1, 2022.</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z8a3abeb304ce4d8880df08f416c23aaf">

        <tr>
          <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
          <td colspan="2" style="vertical-align: middle;">
            <div style="color: rgb(0, 0, 0); font-weight: bold;">PDS Biotechnology Corporation</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">&#160;</td>
          <td style="width: 44.59%; vertical-align: middle;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">By:</div>
          </td>
          <td style="width: 44.59%; vertical-align: middle; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="color: rgb(0, 0, 0);">/s/ Frank Bedu-Addo</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Name:</div>
          </td>
          <td style="width: 44.59%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Frank Bedu-Addo, Ph.D.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.59%; vertical-align: middle;">&#160;</td>
          <td style="width: 5%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">Title:</div>
          </td>
          <td style="width: 44.59%; vertical-align: middle;">
            <div style="color: rgb(0, 0, 0);">President and Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center;"><br>
    </div>
    <div><br>
    </div>
    <hr noshade="noshade" align="center" style="height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); text-align: center; margin-left: auto; margin-right: auto; border: medium none;"></div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "brhc10035847_s8.htm", "description": "S-8", "secsgml_size_bytes": 25740}]
{"company-data": {"conformed-name": "PDS Biotechnology Corp", "cik": "0001472091", "assigned-sic": "2834", "irs-number": "264231384", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-264048", "film-number": "22795852"}, "business-address": {"street1": "25B VREELAND ROAD", "street2": "SUITE 300", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932", "phone": "800-208-3343"}, "mail-address": {"street1": "25B VREELAND ROAD", "street2": "SUITE 300", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932"}, "former-company": {"former-conformed-name": "Edge Therapeutics, Inc.", "date-changed": "20090911"}}
As filed with the Securities and Exchange Commission on April 1, 2022
Registration No. 333-_________
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
PDS Biotechnology Corporation
(Exact name of registrant as specified in its charter)
Delaware
26-4231384
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
25B Vreeland Road, Suite 300
Florham Park, NJ
07932
(Address of Principal Executive Offices)
(Zip Code)
Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan
(Full title of the plan)
Frank Bedu-Addo
President and Chief Executive Officer
PDS Biotechnology Corporation
25B Vreeland Road, Suite 300
Florham Park, NJ 07932
(800) 208-3343
(Name, address and telephone number, including area code, of agent for service)
Copies t
o:
Fahd M.T. Riaz, Esq.
Emilio Ragosa, Esq.
DLA Piper LLP (US)
One Liberty Place
1650 Market Street, Suite 5000
Philadelphia, PA  19103-7300
(215) 656-3316
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated
      filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.
Large Accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
      Section 7(a)(2)(B) of the Securities Act. ☐
Part II
Information Required In The Registration Statement
This Registration Statement relates to the registration of an additional 2,616,163 shares (the "
Shares
") of PDS Biotechnology Corporation's (the "
Registrant
")
          Common Stock, par value $0.00033 per share. The Shares are securities of the same class and relate to the same employee benefit plan, the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, which was amended and
          restated effective as of December 8, 2020 (in the form attached hereto as Exhibit 99.1) (the "
2014 Plan
"), as those
          registered pursuant to the Registrant's registration statements on Form S-8, previously filed with the Securities and Exchange Commission on
October

          21, 2015 (Registration No. 333-207545)
,
March 9, 2016 (Registration No. 333-210041)
,
March 3, 2017 (Registration No. 333-216430)
,
March 2, 2018 (Registration No. 333-223389)
,
February 22, 2019 (Registration No. 333-229817)
, and
June 4, 2019 (Registration No. 333-231943)
.
In accordance with General Instruction E of Form S-8, the contents of the Registrant's registration statements filed with the Securities and Exchange Commission
          on
October 21, 2015 (Registration No. 333-207545)
,
March 9, 2016 (Registration No. 333-210041)
,
March 3, 2017 (Registration No. 333-216430)
,
March 2, 2018 (Registration No. 333-223389)
,
February 22, 2019 (Registration No. 333-229817)
, and
June 4, 2019 (Registration No. 333-231943)
are incorporated herein by reference (solely to the extent the contents of such
          registration statements relate to the 2014 Plan) and the information required by Part II is omitted, except as supplemented by the information set forth below.
Item 8.
Exhibits.
Exhibit
No.
Description
4.1
Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on October 6, 2015).
4.2
Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission
              on March 18, 2019).
4.3
Certificate of Amendment of the Eighth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed with the Commission
              on March 18, 2019).
4.4
Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Commission on March 15, 2022).
4.5
Form of Certificate of Common Stock (incorporated by reference to Exhibit 4.1 to the Registrant's Pre-Effective Amendment No. 1 to the Registration Statement on Form S-1 (File No. 333- 206416) filed with the
              Commission on September 21, 2015).
5.1*
Opinion of DLA Piper LLP (US).
23.1*
Consent of KPMG LLP.
23.2*
Consent of DLA Piper LLP (US) (included in Exhibit 5.1).
24
Power of Attorney (contained on the signature page hereto).
99.1
Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Commission on December 9, 2020).
107*
Filing Fee Table
*
Filed herewith
SIGNATURE
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on
      Form S-8 and has duly caused this Registration Statement with respect to the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, to be signed on its behalf by the undersigned, thereunto duly authorized, in the City
      of Florham Park, State of New Jersey, on April 1, 2022.
PDS Biotechnology Corporation
By:
/s/ Frank Bedu-Addo
Name:
Frank Bedu-Addo, Ph.D.
Title:
President and Chief Executive Officer